Clinical Efficacy of Bevacizumab Injection Combined with Conventional Platinum-containing Dual-drug Chemotherapy in the Treatment of Non-small Cell Lung Cancer and its Relationship with VEGFR2 Gene Polymorphism
Objective:To study the relationship between the clinical efficacy of platinum-containing double-drug chemotherapy combined with bevacizumab in the treatment of non-small cell lung cancer(NSCLC)and vascular endothelial growth factor receptor 2(VEGFR2)gene polymorphism.Methods:A total of 108 patients with NSCLC in Henan Provincial People's Hospital from June 2021 to January 2023 were selected as the research objects.According to the random number method,they were divided into control group and experimental group,with 54 patients in each group.The control group was treated with platinum-containing double-drug chemotherapy,and the experimental group was treated with bevacizumab on the basis of the control group.The clinical efficacy and immune function indexes of the two groups were compared,and the relationship between the clinical efficacy and VEGFR2 gene polymorphism in the experimental group was analyzed.Results:The total clinical effective rate of the experimental group was 81.48%,which was higher than 61.11%of the control group(P＜0.05).The levels of CD8+,CD4+and CD3+in the experimental group were higher than those in the control group after chemotherapy(P＜0.05).The PFS and OS of patients with CC type were higher than those of CT/TT type(P＜0.05).Conclusion:Bevacizumab combined with platinum-containing double-drug chemotherapy is effective in the treatment of NSCLC.It inhibits tumor angiogenesis and improves prognosis by binding VEGF,blocking the interaction of receptors such as VEGF and VEGFR2.
NETL
NSTL
万方数据
